We further validated the fact that the NAT-based models outperformed the tumor-based models, even after correcting the batch effect in the two datasets, i.e., the SMC-CRC transcriptomes (i.e., the transcriptomes generated in the present study) and the TCGA-COAD transcriptomes, by testing which one of these two types of models better predicted the three-year survivals of the TCGA-COAD patients, when NAT- or tumor-derived transcriptomes of TCGA-COAD were used as inputs to the models. The gene discussed is BRD2; the disease is colorectal carcinoma.